ClinicalTrials.gg
CompletedNCT06131372Updated Sep 24, 2026

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

A Phase 2 interventional study of Cagrilintide and Semaglutide in Chronic Kidney Disease, Type 2 Diabetes and Obesity, sponsored by Novo Nordisk A/S. Completed at 129 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
4th of 18
626 · median 128
Started
2024
with 4 others
Phase 2
5 of 29
1 open now
Registered
18th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 2, and was the 18th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age 18 years or above at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
  • (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2) at screening. BMI will be calculated in the eCRF (electronic case report form) based on height and body weight at screening.
  • less than or equal to (≤) 10.5% (91 millimoles per mole [mmol/mol]) as assessed by central laboratory at screening.
  • Kidney impairment defined by serum creatinine and cystatin C-based ≥ 15 and \< 90 milliliters per minutes per 1.73\^m\^2 (mL/min/1.73 m\^2) (CKD-EPI 2021) as assessed by central laboratory at screening.
  • Albuminuria defined by UACR ≥ 100 and \< 5000 milligram per gram (mg/g) as assessed by central laboratory at screening.
  • Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  • Congenital or hereditary kidney diseases including polycystic kidney disease, kidney diseases including glomerulonephritis or congenital urinary tract malformations.
  • Use of any glucagon-like peptide-1 receptor agonist (GLP-1RA) (including medication with GLP-1RA activity, e.g., GIP/GLP-1RA) or amylin analogue within 60 days prior to screening.
  • Myocardial infarction, stroke, , or hospitalization for unstable angina pectoris within 60 days before screening.
  • Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Presence or history of malignant neoplasms or in situ carcinomas (other than basal or squamous cell skin cancer, low-risk prostate cancer, or in-situ carcinomas of the cervix or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN) within 5 years before screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive cagrilintide and semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Experimental
    Semaglutide

    Participants will receive semaglutide and placebo matched to cagrilintide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.

    Drug: Semaglutide · Drug: Placebo

  • Experimental
    Cagrilintide

    Participants will receive cagrilintide and placebo matching to semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.

    Drug: Cagrilintide · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously once weekly for 26 weeks.

    Drug: Placebo

Interventions

  • Participants will receive Cagrilintide subcutaneously.

  • Participants will receive semaglutide subcutaneously.

  • DrugPlacebo

    Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in urinary albumin-to-creatinine ratio (UACR)

    Measured in ratio to baseline.

    Time frame: From baseline (week 0) to end of treatment (week 26)

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR) (creatinine and cystatin C-based chronic kidney disease (CKD)-Epidemiology Collaboration equation (EPI) 2021)

    Measured in milliliters per minute per 1.73 meters square (mL/min/1.73 m\^2).

    Time frame: From baseline (week 0) to end of treatment (week 26)

  2. Change in eGFR (creatinine-based CKD-EPI 2021)

    Measured in mL/min/1.73 m\^2.

    Time frame: From baseline (week 0) to end of treatment (week 26)

  3. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 26)

  4. Achievement of greater than or equal to (≥) 5 % weight reduction

    Count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 26)

  5. Achievement of ≥ 10 % weight reduction

    Count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 26)

  6. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 26)

  7. Change in glycated haemoglobin (HbA1c)

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 26)

  8. Change in systolic blood pressure

    Measured in millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 26)

  9. Change in diastolic blood pressure

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 26)

  10. Number of treatment emergent adverse events (TEAEs)

    count of events.

    Time frame: From baseline (week 0) to end of study (week 32)

  11. Number of treatment emergent serious adverse events (SAEs)

    count of events.

    Time frame: From baseline (week 0) to end of study (week 32)

  12. Number of clinically significant hypoglycaemic episodes (level 2) ( blood glucose less than [<] 3.0 millimoles per liter [mmol/L] (54 milligram per deciliter [mg/dL]))

    Count of episodes.

    Time frame: From baseline (week 0) to end of study (week 32)

  13. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Count of episodes.

    Time frame: From baseline (week 0) to end of study (week 32)

07

Study locations

129 sites
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Valley Research
    Fresno, California 93720, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Life Spring Research Foundation LLC
    Miami, Florida 33130, United States
  • Advent Health Translational Research Institute
    Orlando, Florida 32804, United States
  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Univ. of Nebraska Medical Center_Omaha
    Omaha, Nebraska 68198, United States
  • Albany Medical College
    Albany, New York 12203, United States
  • NYU Langone Nephrology Associates
    Mineola, New York 11501, United States
  • New York University Grossman School of Medicine
    New York, New York 10016, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Eastern Nephrology Associates, PLLC
    New Bern, North Carolina 28562, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • Ohio- Advanced Medical Research
    Maumee, Ohio 43537, United States
  • Heritage Valley Multispeciality Group Inc
    Beaver, Pennsylvania 15009, United States
  • Main Street Physician's Care
    Little River, South Carolina 29566, United States
  • Osvaldo A. Brusco MD
    Corpus Christi, Texas 78414, United States
  • Southwest Houston Research Ltd
    Houston, Texas 77099, United States
  • Clinical Advancement Center
    San Antonio, Texas 78212, United States
  • Clinical Investigation Specialists Inc, Kenosha
    Kenosha, Wisconsin 53144, United States
  • Mautalen Salud e investigación
    CABA, Buenos Aires C1128 AAF, Argentina
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, Buenos Aires B7600GNY, Argentina
  • Fundación CESIM
    Santa Rosa, La Pampa Province 6300, Argentina
  • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
    Buenos Aires, C1425AGC, Argentina
  • Centro Médico Privado San Vicente Diabetes
    Córdoba, X5006IKK, Argentina
  • Instituto Pró-Renal Brasil
    Curitiba, Paraná 80440-020, Brazil
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas
    São Paulo, São Paulo 01228-200, Brazil
  • Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos
    São Paulo, 04038-002, Brazil
  • Centricity Research Calgary Endocrinology
    Calgary, Alberta T2H 2G4, Canada
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Centricity Research Vaughn Endocrinology
    Concord, Ontario L4K 4M2, Canada
  • Centricity Research Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
  • Hamilton Medical Research Group
    Hamilton, Ontario L8L 5G4, Canada
  • Bluewater Clin Res Group Inc
    Sarnia, Ontario N7T 4X3, Canada
  • UHN-Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Ctr de recherche Clinique de Laval
    Laval, Quebec H7T 2P5, Canada
  • Centre Medical Acadie
    Montreal, Quebec H4N 2W2, Canada
  • Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu
    Le Creusot, 71200, France
  • Hôpitaux Saint-Joseph & Marie-Lannelongue
    Paris, 75674, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers, 86000, France
  • Chu de Reims-Hopital Maison Blanche
    Reims, 51092, France
  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec
    Saint-Herblain, 44800, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
    Toulouse, 31059, France
  • Centre de Recherche Clinique Portes Du Sud
    Vénissieux, 69200, France
  • University General Hospital Of Heraklion
    Heraklion, Crete 71500, Greece
  • "Laiko" General Hospital of Athens
    Athens, 11527, Greece
  • Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
    Athens, 11527, Greece
  • General hospital of Athens 'G.Gennimatas'
    Athens, 11527, Greece
  • Iatriko Athinon 'Palaiou Falirou'
    Athens, 17562, Greece
  • "Laiko" General Hospital of Athens
    Athens, GR-11527, Greece
  • Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
    Athens, GR-11527, Greece
  • General hospital of Athens 'G.Gennimatas'
    Athens, GR-11527, Greece
  • General Hospital of Lamia
    Lamia, 35100, Greece
  • Univ Gen Hospital Larisa
    Larissa, 41110, Greece
  • Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease
    Larissa, GR-41110, Greece
  • General University Hospital of Patras,Nephrology clinic
    Pátrai, GR-26504, Greece
  • General University Hospital of Patras,Nephrology clinic
    Rio, Patra, 26504, Greece
  • General Hospital of Thessaloniki 'G. Gennimatas
    Thessaloniki, 54635, Greece
  • "Ippokrateio" G.H. of Thessaloniki
    Thessaloniki, 54642, Greece
  • General Hospital of Thessaloniki "Ippokrateio"
    Thessaloniki, 54642, Greece
  • General Hospital of Thessaloniki "G.Papanikolaou"
    Thessaloniki, 57010, Greece
  • General Hospital of Thessaloniki 'G. Gennimatas
    Thessaloniki, GR-54635, Greece
  • "Ippokrateio" G.H. of Thessaloniki
    Thessaloniki, GR-54642, Greece
  • General Hospital of Thessaloniki "G.Papanikolaou"
    Thessaloniki, GR-57010, Greece
  • PTE-AOK II. Belgyogyaszati Klinika es Nephrologiai Centrum
    Pécs, Baranya Vármegye 7623, Hungary
  • Lausmed Kft.
    Baja, Bács-Kiskun county 6500, Hungary
  • Belinus Bt.
    Debrecen, Hajdú-Bihar 4025, Hungary
  • Siófoki Kórház, Diabetológiai Szakrendelés
    Siófok, Somogy County 8600, Hungary
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
  • Szent Margit Rendelőintézet Nonprofit Kft.
    Budapest, 1032, Hungary
  • Békés Megyei Központi Kórház
    Gyula, 5700, Hungary
  • Endolife Specialty Hospitals
    Guntur, Andhra Pradesh 522001, India
  • NIZAM'S Institute of Medical Sciences
    Hyderabad, Andhra Pradesh 500082, India
  • Sunrise Hospital
    Vijayawada, Andhra Pradesh 520002, India
  • Lifecare Hospital and Research Centre
    Bengaluru, Karnataka 560066, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • King Edward Memorial Hospital
    Pune- Maharashtra, Maharashtra 411011, India
  • Maulana Azad Medical College
    Delhi, New Delhi 110002, India
  • Madras Diabetes Research Foundation
    Chennai, Tamil Nadu 600086, India
  • Shri Mahant Indiresh Hospital
    Dehradun, Uttarakhand 248001, India
  • Seino Internal Medicine Clinic_Internal medicine
    Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
  • Nippon Kokan Fukuyama Hospital_Diabetology
    Fukuyama-shi, Hiroshima, 721-0927, Japan
  • Sasaki Internal Medicine
    Hokkaido, 062-0007, Japan
  • Nishiyamado Keiwa Hospital_Internal Medicine
    Ibaraki, 331-0133, Japan
  • Kanno Naika_Internal Medicine
    Mitaka-shi, Tokyo, 181-0013, Japan
  • Minami Akatsuka Clinic_internal medicine
    Mito-shi, Ibaraki, 311-4153, Japan
  • Minami Akatsuka Clinic
    Mito-shi, Ibaraki, 311-4153, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
  • Fukuwa Clinic
    Tokyo, 104-0031, Japan
  • Osteo Medic s.c. Artur Racewicz Jerzy Supronik
    Bialystok, Podlaskie Voivodeship 15-351, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
    Bialystok, Podlaskie Voivodeship 15-435, Poland
  • Kresmed Sp. z o. o.
    Bialystok, Podlaskie Voivodeship 15-481, Poland
  • M2M Med. Badania Sp. z o.o.
    Chorzów, Silesian Voivodeship 41-500, Poland

Showing the first 100 of 129 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2025, 17 months.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 17 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 14, 2023
StartActual
Apr 1, 2024
Primary completionActual
Sep 24, 2025
CompletionActual
Nov 6, 2025
Results delay requested
Sep 23, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06131372
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Apr 1, 2024
Primary completion
Sep 24, 2025
Completion
Nov 6, 2025
Last update
Sep 24, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion